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ABSTRACT
Aim: To assess KIT and PDGFRA mutations frequencies in
a Portuguese series of gastrointestinal stromal tumours
(GISTs).
Methods: 78 GISTs were evaluated for CD117 expression
and screened for mutations in KIT (exons 9, 11, 13, 14
and 17) and PDGFRA (exons 12, 14 and 18) genes.
Results: KIT activating mutations were identified in 44
(56%) of the 78 GISTs. Forty cases (91%) presented a
mutation in KIT exon 11, and 4 (9%) in exon 9. One case
showed a 4 bp deletion in intron 14. PDGFRA mutations
were observed in 5 cases (6%): 2 (3%) in exon 12 and 3
(4%) in exon 18. Survival analysis was performed in 63 of
the 78 GISTs. The presence of mutated KIT was
significantly correlated with shorter survival of patients
(p = 0.0460), and inversely associated with epithelioid
histological type of GISTs (p = 0.0064).
Conclusions: Overall, the incidence of both KIT and
PDGFRA mutations in these Portuguese series was 63%,
being in agreement with other studies, mainly of Iberian
populations. The great majority of mutations were located
in KIT exon 11, statistically associated with worse
prognosis and indicative of favourable response to
imatinib-based therapy in this Portuguese series of GISTs.
Gastrointestinal stromal tumours (GISTs)
although rare, are considered to be the most
frequent gastrointestinal mesenchymal tumours
in humans.1 A Scandinavian study estimated the
incidence of GISTs to be between 20 and 40 per
million.2 In Portugal, as far as we know, an
epidemiological study is yet to be done.
The cellular origin of GISTs is not fully under-
stood, but they are thought to arise from inter-
stitial cells of Cajal or their precursors, due to their
similar positive KIT (CD117) and CD34 staining
and negative staining for both desmin and S-100
protein immunostaining.1 3 GISTs are rarely found
outside the gastrointestinal tract, being most
commonly found in the stomach (40–70%), small
intestine (20–50%) and colon or rectum (5–
15%).1 2 4 Nowadays, the diagnosis of GISTs is
partially dependent on tumour cells overexpression
of CD117 together with CD34.5 The expression of
such immunohistochemistry features is useful to
differentiate GISTs from other mesenchymal
tumours of the gastrointestinal tract, namely
leiomyomas and leiomyosarcomas, nerve sheath
tumours, and other primary and metastatic
tumours possibly occurring in this location.1 2 4
KIT belongs to the class III receptor tyrosine
kinases (RTKs), which also include platelet-derived
growth factor A and B (PDGFRA, PDGFRB),
colony stimulating factor-1 receptor (CSF1R) and
FMS-related tyrosine kinase 3 (FLT3).6 These RTKs
are characterised by the presence of an extracellular
domain, a transmembrane domain, a juxtamem-
brane domain, and an intracellular domain where
the two kinase domains are lodged.7 RTK activa-
tion occurs when by ligand binding, the receptor
dimerises and suffers conformational transforma-
tions, which induce activation of the kinase
domains. These, in turn, lead to activation of
important intracellular signalling pathways, such
as RAS/mitogen activated protein kinase (RAS/
MAPK), phosphoinositide-3 kinase (PI3K), and
signal transducers and activators of transcription
(STAT), which regulate many physiological func-
tions such as cell survival, proliferation, differentia-
tion, adhesion and apoptosis.7 8
GISTs are molecularly characterised by muta-
tions in KIT oncogene, located in the long arm of
chromosome 4 (4q11–12).9 There is a broad
spectrum of KIT mutations in GISTs, ranging from
20% to 80%, most of them being located in the
juxtamembrane domain (exon 11), followed by
mutations in the extracellular domain (exon 9),
and seldom in the kinase (exon 13 and 17) and ATP
pocket (exon 14) domains.10–12 Later studies
reported the presence of activating mutations in
the PDGFRA oncogene in wild-type KIT bearing
GISTs.13 14 PDGFRA is also located at 4q11–12 and
exhibits similar RTK cellular functions.13 14 The
hotspot regions in this gene lie in the juxtamem-
brane (exon 12) and kinase (exons 14 and 18)
domains, and have been reported in 5–12% of
cases.12 14 The frequency of KIT/PDGFRA muta-
tions in GISTs varies from series to series, probably
reflecting epidemiological and methodological dif-
ferences in the various studies on record.10 12
Until recently, the treatment of GISTs was
limited to surgical removal of the tumour.
Unfortunately, even in patients where the tumour
was completely and successfully removed, there
was a high probability of recurrence.1 The devel-
opment of imatinib mesylate (Glivec/Gleevec,
Novartis, Basel, Switzerland), a selective inhibitor
of RTKs, has brought new hope for GIST patients.
Imatinib targets KIT by competing with its ATP
binding site, preventing further phosphorylations
of downstream intracellular signalling molecules
responsible for its oncogenic properties.15 16 Several
studies have showed the importance of KIT and
PDGFRA molecular status in the imatinib
response.10 12 It has been reported that patients
with tumours harbouring exon 11 KIT mutations
are more likely to respond to imatinib therapy than
those with either exon 9 KIT mutations or
undetectable mutations.10 12
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In Portugal, the incidence of both KIT and PDGFRA
mutations in GISTs is, to the best of our knowledge, unknown.
Since different genotypic features give rise to different drug
responses and thus different prognosis, it becomes important to
define which patients will positively respond to imatinib
treatment. Therefore, we characterised the occurrence of KIT
and PDGFRA mutations in a series of Portuguese GIST patients.
MATERIALS AND METHODS
Tissue samples
Seventy-eight formalin-fixed and paraffin-embedded consecu-
tively diagnosed primary, previously untreated, sporadic GISTs,
classified according to World Health Organization criteria5 and
risk group,17 were retrieved from files (1989–2005) from the
Pathology Department of S. Joa˜o Hospital, Porto, Portugal. All
patients were Caucasian and of Portuguese origin, with a mean
age of 61.7 years (range 20–88). Thirty-eight (48.7%) patients
were female and 40 (51.3%) were male. Follow-up data,
managed according to the guidelines of the European Society
of Medical Oncology,18 were available in 63 patients (range 0.2–
206.0 months, mean 122.8 (12.1) months, median 132.6 (26.8)
months) in September 2006.
Immunohistochemistry
The immunohistochemistry procedure was performed according
to the streptavidin–biotin–peroxidase complex principle, using
rabbit polyclonal anti-human antibodies raised against CD117
(dilution 1:500; clone A 4502, DAKO, Carpinteria, Denmark),
actin (dilution 1:100; clone HHF35, DAKO), desmin (dilution
1:50; Zymed Laboratories, San Francisco, California, USA), S100
protein (dilution 1:1000; DAKO) and endothelial cell marker
CD34 (dilution 1:40; clone QBEnd/10, NovoCastra Laboratories,
Newcastle-upon-Tyne, UK). Briefly, deparaffinised and rehy-
drated slides were subjected to 10 min incubation in 3% hydrogen
peroxide in methanol, in order to inhibit endogenous peroxidase.
No antigen retrieval was used. After incubation with primary
antibody at room temperature for 30 min, the secondary
biotinylated goat anti-polyvalent antibody was applied for
10 min, followed by incubation with streptavidin–peroxidase
complex. The immune reaction was visualised by DAB as a
chromogen (Ultravision Detection System Anti-polyvalent, HRP/
DAB; Lab Vision, Fremont, California, USA). Any (strong/weak,
focal, moderate or diffuse) membrane (CD117) and/or cytoplasm
(CD117, actin, desmin, and CD34), and nuclear (S100 protein)
immunoreactivity of the cells was considered as positive staining.
Appropriated positive and negative controls were included in each
run: interstitial cells of Cajal in a section of normal intestine were
used as positive control for CD117, smooth layers for actin and
desmin, small nerves for S100 protein, and vessels for CD34. For
negative controls, primary antibodies were omitted. Mast cells,
smooth layers, small nerves, and vessels were used as internal
positive controls in the cases tested. All sections were counter-
stained with haematoxylin.
DNA isolation
Selected areas containing at least 85% of tumour tissue were
macrodissected into a microfuge tube using a sterile needle
(Neolus, 25 G, 0.5 mm). DNA isolation was performed as
described previously.19 Briefly, the dissected tissue was depar-
affinised by a serial extraction with xylol and ethanol (100%–
70%–50%) and allowed to air-dry. DNA was extracted using
Qiagen’s QIAamp DNA Micro Kit (Qiagen, Hilden, Germany),
following the manufacturer’s instructions. DNA samples were
stored at 220uC for further analysis.
KIT mutation analysis
KIT mutation analysis was performed as described pre-
viously.19 20 DNA was subjected to PCR amplifications followed
by direct sequencing for exon 11, and pre-screening by single
strand conformational polymorphism (SSCP) analysis for exons
9, 13, 14 and 17, followed by direct sequencing of SSCP positive
cases. Briefly, the PCR reaction was carried in a final volume of
Figure 1 Morphological and
immunohistochemical features of
gastrointestinal stromal tumours (GISTs).
(A) spindle cell and (B) epithelioid tumour
cells with (C) membranar/cytoplasmic
and (D) cytoplasmic/paranuclear dot
immunoreactivity for CD117. Note
immunoreactivity of interstitial cells of
Cajal (C, inset). H&E and ABC
immunohistochemistry (2006).
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25 ml, under the following conditions: 16 buffer (Bioron,
Ludwigshafen, Germany); 1.5 mM MgCl2 (Bioron); 200 mM
dNTPs (Fermentas, Hanover, Maryland, USA); 0.5 mM primers
(previously described by Corless et al,21 except for exon 14: 59-TCT
CAC CTT CTT TCT AAC CTT TTC TT-39 (forward); 59-CCC
ATG AAC TGC CTG TCA AC-39 (reverse); MWG-Biotech,
Ebersberg, Germany); and 1 unit of Super Hot Taq Polymerase
(Bioron, Germany). SSCP analysis of exons 9, 13, 14 and 17 was
performed in a 16 MDE gel (MDE: mutation detection
enhancement, Cambrex, Charles City, Iowa, USA), with 6%
glycerol addition in the exon 13 analysis, and 3% glycerol addition
in exon 14 analysis. PCR product (20 ml) was incubated at 95uC
for 10 min with an equal volume of formamide loading buffer
(98% formamide, 10 mM EDTA, and 1 mg/ml bromophenol blue
and xilene cyanol). SSCP gels were run at 20uC. Samples with a
SSCP pattern different from the normal pattern were directly
sequenced. All cases were confirmed twice with a new PCR
amplification, SSCP and direct sequencing analysis.
PDGFRA mutation analysis
Tumours bearing a wild-type KIT gene were further screened for
hotspot PDGFRA mutations (exons 12, 14 and 18) as previously
described.19 20 Briefly, the PCR reaction was carried out in a final
volume of 25 ml, under the following conditions: 16 buffer
(Bioron); 1.5 mM MgCl2 (Bioron); 200 mM dNTPs (Fermentas);
0.5 mM primers (previously described by Heinrich et al13; MWG-
Biotech) and 1 unit of Super Hot Taq Polymerase (Bioron). PCR
was followed by direct sequencing. All cases were confirmed twice
with a new PCR amplification and direct sequencing analysis.
Statistical analysis
The available clinical and molecular data were analysed with
StatView for Windows, V.5.0. Overall survival time analysis using
Kaplan–Meyer and log rank tests was performed with SPSS for
Windows, V.14.0. Probability values ,0.05 were considered
significant.
RESULTS
Immunohistochemistry
Strong membrane and/or cytoplasm tumour cells immunoreactiv-
ity for CD117 was found in variably focal, moderate or diffuse
areas in 72 (92%) GIST cases (fig 1). In three cases, CD117
immunoreactivity was weak. Six GIST cases (8%) did not show
CD117 immunoreactive tumour cells. Interstitial cells of Cajal and
mast cells, used as internal positive controls, were always variably
observed in each case. Table 1 summarises statistical analysis of
CD117 immunostaining and clinical–pathological features.
CD117 immunoreactivity was significantly associated
(p = 0.015) with spindle cell and epithelioid GIST subtypes. The
frequency and expression features of the other antibodies was
variable from case to case, and within the same tumour, as follows:
actin (51%), desmin (6%), S100 protein (18%), and CD34 (73%);
immunoexpression was observed in focal areas/rare tumour cells
for actin, desmin, and S100 protein, whereas CD34 immunoex-
pression was found in moderate or diffuse areas (data not shown).
Four of the six CD117 negative GISTs expressed CD34 without
any tumour cell expression for the other markers tested.
KIT mutation analysis
Mutation screening analysis revealed that 44 of 78 GISTs (56%)
presented KIT activating mutations (table 2). Forty cases
showed mutation in exon 11 (91%, 40/44) and four cases in
exon 9 (9%, 4/44). Among the exon 11 mutations, we observed
3–54 bp in-frame deletions in 24 tumours (60%, 24/40), either
alone (62%, 15/24) or associated with missense mutations or
insertions (38%, 9/24), single base substitutions in 15 tumours
(38%, 15/40) and an in-frame insertion associated with a point
mutation in 1 tumour (2%, 1/40). Additionally, a silent
mutation (Y570Y) was detected in two GISTs. The exon 9
sequence alterations consisted of Ala–Tyr duplication between
codons 502 and 503 in three GIST cases, and a point mutation
(G470R) in one case. One silent mutation was detected in both
exons 13 and 17 (P627P and S865S, respectively). Also, a 4 bp
deletion was detected affecting the intronic sequence following
exon 14 (IVS14+24:del4). In addition, to exclude the possibility
of false-negatives in the SSCP screening at exons 9, 13, 14 and
17, 10 KIT wild-type GISTs were direct sequenced for all exons.
No additional mutations were identified.
Table 3 shows statistical analysis of KIT mutations and
clinical–pathological features. No correlation was detected
between KIT mutation status and CD117 expression
(p = 0.39). However, all but two GISTs harbouring KIT
mutation were positive for CD117 expression. Additionally,
the three GISTs with weak CD117 immunoreactivity depicted
wild-type KIT. A statistically significant correlation was
obtained between the epithelioid morphology and lack of KIT
mutation (p = 0.0064). The presence of mutated KIT was
significantly associated with shorter survival of patients
(p = 0.0460) (fig 2). No correlation was obtained between any
specific type of KIT mutation (point mutation, deletion, or
mixed mutation), or its location (exon 9 or exon 11), and
patient survival (data not shown).
PDGFRA mutation analysis
In KIT wild-type GISTs, PDGFRA activating mutations were
identified in five cases; two in exon 12, and three in exon 18
Table 1 Correlation analysis of CD117 with clinical and pathological
features of gastrointestinal stromal tumours (n = 63)
Parameter (n = 63)
CD117 negative
(%)
CD117 positive
(%) p value
Age, y (SD) 54.6 (12.1) 61.2 (15.5) 0.37
Gender 0.13
Male 13.7 86.3
Female 3.3 96.7
Location 0.18
Gastric 5.9 94.1
Small intestine 5.0 95.0
Other 25.0 75.0
Dimension (cm) 0.76
,5 4.0 96.0
>5 5.7 94.3
Mitotic index (HPF) 0.34
,5 11.4 88.6
5–10 0.0 100.0
.10 0.0 100.0
Risk grade 0.93
VLR–LR 5.0 95.0
IR 6.7 93.3
HR 4.0 96.0
Histological type 0.02
Spindle cell 2.5 97.5
Epithelioid 0.0 100.0
Mixed 25.0 75.0
Follow-up, months (SD) 92.3 (32.8) 120.8 (12.6) 0.96
HPF, high power field (6400); VLR, very low risk; LR, low risk; IR, intermediate risk;
HR, high risk.
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(table 4). The mutations in exon 12 consisted of a point
mutation (D583G) and an in-frame deletion (583del586). Two
cases disclosed a point mutation (D842V) in exon 18; there was
another case with a point mutation (I843T) together with an in-
frame deletion (844del847). In addition, we identified two silent
mutations, one in exon 12 (D577D) and another in exon 18
(I834I). No mutation was observed in exon 14 of PDGFRA.
Furthermore, mutational analysis of exons 12 and 18 showed
the presence of a known homozygous substitution A.G
(polymorphism R) in the third position of the codon for proline
567 in exon 12, and an insertion in intron 18 (IVS18-50insA).
All GISTs with PDGFRA mutations showed CD117 immu-
noreactive tumour cells.
DISCUSSION
The intensive cancer research in the last decade has highlighted
the fundamental role of RTKs, in particular of KIT and
PDGFRA in GIST pathogenesis.10 These two RTKs are of great
value for therapeutic management as a result of the develop-
ment of RTK inhibitors, such as imatinib and sunitinib.22–24
There is, however, insufficient epidemiological data on the
frequency and type of mutations in the KIT and PDGFRA genes
in GISTs from countries in southern Europe countries, such as
Portugal.
In this study, we have shown that 92% of GISTs express
CD117, irrespective of the topography, age or gender, in
accordance with previous studies in other populations.25 26 No
statistically significant correlation was depicted between CD117
expression and presence of KIT mutations (p = 0.3933). In fact,
two of the six CD117-negative GISTs contained a KIT mutation
(a missense mutation in exon 9, and a three base-pair deletion in
exon 11). Other authors have also encountered KIT mutations
in CD117-negative GIST cases.27 Our molecular study was
useful for the definitive diagnosis of GIST in 2/6 CD117
negative cases. The frequency of the CD117-negative wild-type
cases for KIT and PDGFRA mutations found in our series (5%),
fits with results described in the literature.27
We showed the presence of KIT mutations in 56% of GIST
cases, 91% (40/44) being located in exon 11. These frequencies
are in accordance with previously published ranges for other
populations (30–80%), particularly those of the Iberian
Peninsula.1 10 28 In 75% (30/40) of these cases, mutations were
clustered in the region between codons 550 and 561, known to
be the most frequently altered section of exon 11, with 57% (17/
30) affecting codon 557 or 558. These two codons are reported
to be associated with the metastatic behaviour of GISTs.10 29
However, of these 17 GIST cases, only four recurred (4/17,
24%). Even though it has been previously reported that all point
mutations occur exclusively in codons 557, 559, 560 and 576, we
have additionally encountered a novel point mutation in codon
570 (Y570F).1 Mutations in KIT exon 9 have been correlated
with a small intestinal topography, but only one of our four
GIST cases harbouring a mutation in this exon was located in
the small intestine.1 10 In the present study, and in agreement
with previous reports, KIT mutation positive status was shown
to be associated with worse GIST prognosis, translated into
shorter patient survival.10
Figure 2 Kaplan–Meier curve for the 63 patients with gastrointestinal
stromal tumours, regarding KIT alterations. Patients having a wild-type
KIT (n = 27) have a better prognosis than patients having tumours
harbouring mutated KIT (n = 36) (p = 0.046).
Table 3 Correlation of KIT mutations with clinical-pathological features
of gastrointestinal stromal tumours (n = 63)
Parameter
KIT mutation
negative (%)
KIT mutation
positive (%) p value
Age, y (SD) 57.2 (16.6) 62.8 (14.2) 0.16
Gender 0.94
Male 43.3 56.7
Female 42.4 57.6
Location 0.27
Gastric 51.4 48.6
Small intestine 35.0 65.0
Other 25.0 75.0
Dimension (cm) 0.93
,5 44.0 56.0
>5 42.8 57.2
Mitotic index (50 HPF) 0.80
,5 45.4 54.5
5–10 44.4 55.6
.10 33.3 66.7
Risk grade 0.70
VLR–LR 40.0 60.0
IR 53.3 46.7
HR 42.3 57.7
Histological subtype 0.01
Spindle 41.5 58.5
Epithelioid 100.0 0.0
Mixed 25.0 75.0
CD117 expression 0.39
Positive 40.4 59.6
Negative 60.0 40.0
Follow-up, months (SD) 148.7 (17.1) 100.8 (12.1) 0.05
HPF, high power field (6400); VLR, very low risk; LR, low risk; IR, intermediate risk;
HR, high risk.
Table 4 Amino acid sequence of exons 12 and 18 of wild-type and
mutated PDGFRA protein
Exon 12 580
Wild type L P Y D S R W E F P
Case 4 L P Y G S R W E F P
Case 71 L P Y – – – – E F P
Exon 18 840
Wild type A R D I M H D S N Y
Cases 41, 54 A R V I M H D S N Y
Case 34 A R D T – – – – N Y
–, deleted amino acid residues.
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Concerning PDGFRA, mutations were detected in 6% (5/78)
of our cases, corresponding to 15% of KIT wild-type GISTs.
Two of these mutations are known to be imatinib-resistant
(D842V).22 An association between gastric location and presence
of PDGFRA mutation has been reported.30 In our series,
although the number of cases with mutations in PDGFRA is
low for statistical evaluation (n = 5), 80% (4/5) of mutations
occurred in the stomach.
It is now well established that the response of GIST patients
to imatinib-based therapy is dependent not only on the
presence, but also on the type of KIT and PDGFRA mutation
exhibited.10 16 22 Specifically, mutations affecting the juxtamem-
brane domain (exon 11, partial response in up to 84% of cases)
or the extracellular domain (exon 9, partial response in up to
48%) predict objective response to imatinib.10 16 22 On the other
hand, it is also known that some mutations are responsible for
imatinib resistance, namely in KIT V654A and W670I (exon 13),
D816V and T823D (exon 17), and PDGFRA D842V (exon
18).16 31 32 Of these resistant mutations, only D842V mutation
was detected in two GISTs in our series. Recently, the US Food
and Drug Administration approved a new RTK inhibitor,
sunitinib (Sutent, Pfizer, New York, USA) as a second-line
therapy for GIST patients who experience disease progression in
spite of increased doses of imatinib, mainly due to primary or
acquired secondary imatinib-resistant mutations, or who are
unable to tolerate treatment with imatinib.24 33 Therefore, with
these two RTK inhibitors available, there is an imperative need
to redefine GIST pathological (diagnosis/prognostic) evaluation,
as well as to consider molecular characterisation of both KIT
and PDGFRA, in order to achieve an efficient and predictive
tailored therapeutic management for each individual patient.
In conclusion, we have reported for the first time the
frequency of KIT and PDGFRA mutations in a large series of
Portuguese GIST patients. We have shown the presence of KIT
mutations in 56% of cases and PDGFRA mutations in 6% of
cases. In addition, the presence of mutated KIT was associated
with a shorter patient survival. The great majority of KIT
activating mutations (91%) were located in exon 11, indicative
of a favourable response to imatinib-based therapy in the
management of these patients. Finally, our results might be
useful to integrate a multi-institutional consortium database for
the clarification of the epidemiology, biology and management
of GIST patients.
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Take-home messages
c The frequency of KIT and PDGFRA activating mutations has
been described in a series of Portuguese gastrointestinal
stromal tumours (GISTs).
c Of the Portuguese patients with GISTs, 56% harboured KIT
mutations and 6% exhibited PDGFRA mutations.
c The presence of KIT mutations in GISTs was associated with a
worse patient prognosis; however, these mutations are
indicative of favourable response to imatinib-based therapy.
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